Company intelligence / Profile preview

Xeos

Ghent, East Flanders, Belgiumxeos.care ↗

Ownership: Private
Employees: ~18
Development stage: Preclinical

Overview

The company’s flagship product, the AURA 10 PET/CT Specimen Imager, enables intraoperative molecular imaging of excised specimens in the operating room. It has received both CE marking and FDA approval as of mid-to-late 2023. The system has been installed at six sites in Europe and used primarily for breast and prostate cancer surgeries to help surgeons assess margins intraoperatively and reduce re-surgery rates. Ongoing interventional studies are generating further clinical evidence.

Therapeutic areas: Oncology
Modalities: Device (PET/CT specimen imager)
Industry: Medical Imaging

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Xeos.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xeos.

Explore the full profile